Trial NCT03721679

View at ClinicalTrials.gov 
Org. Study IDs: ONC2018-001

Last trial update was posted on 2021-02-01

MeSH Interventions

Atezolizumab Durvalumab Nivolumab Pembrolizumab Poly ICLC

MeSH Conditions


Other Conditions

Solid Cancer

Stopping Reasons

Recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.

Limitations And Caveats

N/A

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID